Loading…
Arcturus Therapeutics Holdings Inc. is projected to rise to $9.37 by 2027, a +22% move from its current price of $7.66. ARCT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $7.42 | $7.67 | $7.92 | +0.08% |
| May 30 | $7.32 | $7.67 | $8.04 | +0.16% |
| May 31 | $7.25 | $7.68 | $8.13 | +0.24% |
| Jun 1 | $7.19 | $7.68 | $8.21 | +0.32% |
| Jun 2 | $7.14 | $7.69 | $8.28 | +0.40% |
| Jun 3 | $7.10 | $7.70 | $8.35 | +0.48% |
| Jun 4 | $7.06 | $7.70 | $8.41 | +0.56% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.06 | $7.70 | $8.41 | +0.56% |
| Week 2 | $6.84 | $7.75 | $8.77 | +1.13% |
| Week 3 | $6.69 | $7.79 | $9.07 | +1.70% |
| Week 4 | $6.57 | $7.83 | $9.33 | +2.27% |
| Week 5 | $6.48 | $7.88 | $9.58 | +2.84% |
| Week 6 | $6.39 | $7.92 | $9.82 | +3.42% |
| Week 7 | $6.32 | $7.97 | $10.04 | +4.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arcturus Therapeutics Holdings Inc. is a healthcare company that focuses on messenger RNA medicines and the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
The company also lists a portfolio of clinical programs, including ARCT-032 (LUNAR-CF) for cystic fibrosis in Phase 2 and ARCT-810 (LUNAR-OTC) in Phase 2 for OTC deficiency. It also develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU) in Phase 1 for seasonal influenza; and ARCT-2304 (LUNAR-H5N1) in Phase 1 for Pandemic Influenza. Arcturus Therapeutics Holdings Inc.
was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics Holdings Inc. (ARCT) is a healthcare stock currently priced at $7.66 with a market cap of $217.72M and a rank of 3748.
The current price sits within a 30-day range of $6.16 to $9.53, reflecting a bearish technical stance. Key indicators show RSI at 50, a 50-day simple moving average of $7.94 and a 200-day simple moving average of $10.55, with support at $6.69 and resistance at $9.22.
Forecasts project a bullish multi-year trajectory beginning in 2027, with the average price rising from $9.37 in 2027 to $40.10 in 2050 and a cumulative upside (ROI) reaching 423.6% by 2050. The 2026 forecast sets a neutral tone with an average of $7.66, a min of $6.25, and a max of $9.71, ending with an ROI of 0%.
A major floor 30.5% below — a decisive break under it would weaken the trend.
The nearest floor, 12.7% below — buyers have tended to step in here.
The nearest ceiling, 20.4% above — a clean break opens room to run.
A major ceiling 35.6% above — clearing it would confirm fresh momentum.
Key ARCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.15 | Buy | $7.31 | Buy |
| MA 10 | $7.30 | Buy | $7.44 | Buy |
| MA 20 | $7.99 | Sell | $7.74 | Sell |
| MA 50 | $7.94 | Sell | $7.91 | Sell |
| MA 100 | $7.67 | Sell | $8.27 | Sell |
| MA 200 | $10.55 | Sell | $9.77 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.39 | Neutral |
| Stoch RSI (14) | 53.13 | Neutral |
| CCI (20) | -30.74 | Neutral |
| Williams %R (14) | -61.66 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -16.92 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 38.34 | Neutral |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -1.10 | Sell |
| Ultimate (7,14,28) | 46.77 | Neutral |
| Momentum (10) | -0.59 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 7.24 | Buy |
| ADX (14) | 20.26 | Sell |
| ATR (14) | 0.26 | Info |
Near-term technical picture shows a BEARISH sentiment.
The RSI14 is 50, indicating a neutral momentum, while the 50-day SMA sits at $7.94 and the 200-day SMA at $10.55. These moving averages provide a framework for potential near-term price action around the current level.
Price action is constrained within a 30-day range of $6.16 to $9.53, with a support level at $6.69 and a resistance level at $9.22. These levels give a sense of where buyers and sellers may step in over the next weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.25 | $7.66 | $9.71 | 0% | Neutral | |
| $7.28 | $9.37 | $12.87 | +22% | Bullish | |
| $8.41 | $11.20 | $16.04 | +46% | Bullish | |
| $8.90 | $12.19 | $18.04 | +59% | Bullish | |
| $8.77 | $12.32 | $18.74 | +61% | Bullish | |
| $8.65 | $12.44 | $19.40 | +62% | Bullish | |
| $8.97 | $13.18 | $21.00 | +72% | Bullish | |
| $9.68 | $14.53 | $23.61 | +90% | Bullish | |
| $11.65 | $17.83 | $29.50 | +133% | Bullish | |
| $12.28 | $19.15 | $32.22 | +150% | Bullish | |
| $16.74 | $28.48 | $51.39 | +272% | Bullish | |
| $20.21 | $40.10 | $80.09 | +424% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $6.25 | $7.66 | $9.05 | +0.00% |
| June 2026 | $6.87 | $8.11 | $9.82 | +5.89% |
| July 2026 | $6.91 | $8.24 | $10.14 | +1.59% |
| August 2026 | $6.60 | $7.94 | $9.89 | -3.70% |
| September 2026 | $6.54 | $7.91 | $9.96 | -0.34% |
| October 2026 | $6.62 | $8.05 | $10.23 | +1.84% |
| November 2026 | $6.37 | $7.79 | $9.98 | -3.27% |
| December 2026 | $6.12 | $7.52 | $9.71 | -3.43% |
Click any year to see its month-by-month ARCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ARCT price prediction for 2026 points to an average of $7.66 (low $6.25, high $9.71) — a potential gain of 0% on today's $7.66. A consolidation phase looks the most probable path here.
In 2027, ARCT is projected to trade between $7.28 and $12.87, averaging $9.37 — a potential gain of +22% from today's $7.66. That is up +22% on the projected 2026 average. Momentum favours further upside here.
Arcturus Therapeutics Holdings Inc.'s 2028 outlook centres on $11.20, within a $8.41 to $16.04 range. That is up +20% on the projected 2027 average. That marks a +46% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ARCT could reach as high as $18.04, with a base case around $12.19 and support toward $8.90 — roughly +59% from $7.66. Momentum favours further upside here.
Expect ARCT to range from $8.77 to $18.74 through 2030. The $12.32 average target implies a +61% move from current prices. That is up +1% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ARCT price prediction for 2031 points to an average of $12.44 (low $8.65, high $19.40) — a potential gain of +62% on today's $7.66. Momentum favours further upside here.
In 2032, ARCT is projected to trade between $8.97 and $21.00, averaging $13.18 — a potential gain of +72% from today's $7.66. That is up +6% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Arcturus Therapeutics Holdings Inc.'s 2033 outlook centres on $14.53, within a $9.68 to $23.61 range. That is up +10% on the projected 2032 average. That marks a +90% change versus current levels. Momentum favours further upside here.
By 2034, ARCT could reach as high as $29.50, with a base case around $17.83 and support toward $11.65 — roughly +133% from $7.66. Buyers look set to stay in control over this stretch.
Expect ARCT to range from $12.28 to $32.22 through 2035. The $19.15 average target implies a +150% move from current prices. That is up +7% on the projected 2034 average. Momentum favours further upside here.
The ARCT price prediction for 2040 points to an average of $28.48 (low $16.74, high $51.39) — a potential gain of +272% on today's $7.66. Buyers look set to stay in control over this stretch.
In 2050, ARCT is projected to trade between $20.21 and $80.09, averaging $40.10 — a potential gain of +424% from today's $7.66. That is up +41% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ARCT today (≈ 130.548303 ARCT) could be worth
$5,235.56
+$4,235.56 (+424%) by 2050 · US Dollar
Based on the average projected ARCT price of $40.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARCTwould be worth at today's price.
$1,000 invested in ARCT on May 27, 2025 (≈ 83.125521 ARCT) would be worth
$636.74
-$363.26 (-36.3%) today · 0.64× · US Dollar
Based on a ARCT entry price of $12.03 vs. today's $7.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.82 | $1,123.17 | +12.3% |
| 1 month ago | $8.3 | $922.89 | -7.7% |
| 3 months ago | $8.32 | $920.67 | -7.9% |
| 6 months ago | $6.79 | $1,128.13 | +12.8% |
| 1 year ago | $12.03 | $636.74 | -36.3% |
| All time (5.0y) ago | $29.94 | $255.85 | -74.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARCT forecast.
Our base-case forecast reaches $15.00 around 2034.
Implied market cap at $15.00: $426.35M
The multi-year forecast points to a bullish regime from 2027 onward, with the average price rising from $9.37 in 2027 to $40.10 in 2050 and the ROI increasing from 22.4% in 2027 to 423.6% in 2050. Notably, 2030 shows an average of $12.32 with a 60.8% ROI, signaling meaningful longer-term upside.
In 2040, the average rises to $28.48 with a 271.7% ROI, and by 2050 the average reaches $40.10 with a 423.6% ROI. Throughout these years, the sentiment remains bullish, reflecting a steady acceleration in forecasted value.
These figures are estimates and not guarantees; actual results depend on market factors and company developments. The forecast includes a neutral stance in 2026 and a bullish trajectory in subsequent years.
Tap a question to reveal the answer.
The 2030 forecast shows an average of $12.32 with a min of $8.77 and a max of $18.74, a ROI of 60.8%, and bullish sentiment.
Forecasts indicate bullish sentiment from 2027 onward with rising averages (e.g., 2027 avg $9.37) and a positive ROI trajectory through 2030 and beyond, though 2026 is neutral and these are estimates, not guarantees.
The 2050 forecast lists a max of $80.09, an average of $40.10, and a min of $20.21, with a bullish sentiment and a ROI of 423.6%.
The current price is $7.66 and the market cap is $217.72M.
The 30-day range is $6.16 to $9.53, with a support level at $6.69 and a resistance level at $9.22.
Arcturus Therapeutics Holdings Inc. Community Discussion
0Share your Arcturus Therapeutics Holdings Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.